Literature DB >> 7861665

Alendronate modulates osteogenesis of human osteoblastic cells in vitro.

M Tsuchimoto1, Y Azuma, O Higuchi, I Sugimoto, N Hirata, M Kiyoki, I Yamamoto.   

Abstract

The bisphosphonates, which are carbon-substituted pyrophosphates, have been studied extensively both in vivo and in vitro to elucidate their effects on bone tissues and cells. However, because these agents were shown to have a potent inhibitory effect on bone resorption, the majority of studies have focused on only this aspect of bone metabolism. There appears to be less information regarding the direct effect of bisphosphonates on bone formation, so thus we undertook experiments to investigate the effects of bisphosphonates, especially alendronate, on the mineralization and matrix protein synthesis of human osteoblastic cells in vitro. The data show that the bisphosphonates, alendronate, etidronate and pamidronate, suppressed 1,25-dihydroxycholecalciferol (1,25(OH)2D3)-stimulated mineralization of human osteoblastic cells at high concentrations, while relatively lower concentrations of alendronate and etidronate potentiated mineralization of the cells in the presence of 1,25(OH)2D3. The potentiation of mineralization with alendronate was accompanied by increased synthesis of bone matrix proteins, osteocalcin and collagen, and the mRNA of pro alpha(I) collagen. These findings show that in addition to their well-known effects on bone resorption, bisphosphonates have significant and direct effects on osteogenesis in osteoblasts in vitro. The actual mechanism remains to be further investigated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7861665     DOI: 10.1254/jjp.66.25

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  10 in total

Review 1.  Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.

Authors:  Teresita Bellido; Lilian I Plotkin
Journal:  Bone       Date:  2010-08-18       Impact factor: 4.398

Review 2.  Bisphosphonates: effects on osteoblast.

Authors:  Nicola Maruotti; Addolorata Corrado; Anna Neve; Francesco Paolo Cantatore
Journal:  Eur J Clin Pharmacol       Date:  2012-02-09       Impact factor: 2.953

Review 3.  Biphosphonates.

Authors:  J Allgrove
Journal:  Arch Dis Child       Date:  1997-01       Impact factor: 3.791

4.  Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects.

Authors:  Addolorata Corrado; Francesco Paolo Cantatore; Maria Grano; Silvia Colucci
Journal:  Clin Rheumatol       Date:  2005-08-10       Impact factor: 2.980

5.  Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts.

Authors:  O Fromigué; J J Body
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

6.  The interactions of bisphosphonates in solution and as coatings on hydroxyapatite with osteoblasts.

Authors:  A Ganguli; C Henderson; M H Grant; S T Meikle; A W Lloyd; I Goldie
Journal:  J Mater Sci Mater Med       Date:  2002-10       Impact factor: 3.896

7.  Zoledronic acid at subtoxic dose extends osteoblastic stage span of primary human osteoblasts.

Authors:  Susi Zara; Marianna De Colli; Viviana di Giacomo; Vincenzo Luca Zizzari; Chiara Di Nisio; Umberto Di Tore; Vincenzo Salini; Marialucia Gallorini; Stefano Tetè; Amelia Cataldi
Journal:  Clin Oral Investig       Date:  2014-07-24       Impact factor: 3.573

8.  Histopathological Examination of the Effects of Local and Systemic Bisphosphonate Usage in Bone Graft Applications on Bone Healing.

Authors:  Sabit Demircan; S Cemil İşler
Journal:  J Maxillofac Oral Surg       Date:  2020-01-27

9.  Alendronate Can Improve Bone Alterations in Experimental Diabetes by Preventing Antiosteogenic, Antichondrogenic, and Proadipocytic Effects of AGEs on Bone Marrow Progenitor Cells.

Authors:  Sara Rocío Chuguransky; Ana María Cortizo; Antonio Desmond McCarthy
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411

Review 10.  Advanced glycation end products play adverse proinflammatory activities in osteoporosis.

Authors:  Roberta Sanguineti; Alessandra Puddu; François Mach; Fabrizio Montecucco; Giorgio Luciano Viviani
Journal:  Mediators Inflamm       Date:  2014-03-20       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.